AC Immune SA
From Verify.Wiki
 | |
| | |
| AC Immune SA | |
|---|---|
| Type | Public |
| Industry | Biotechnology |
| Founded | 2003 |
| Headquarters | Lausanne, Switzerland |
| Key people | Andrea Pfeifer (Co-Founder & CEO), Jean-Fabien Monin (CFO), Andreas Muhs (CSO) [1] |
| Investors | Dietmar Hopp |
| Number of employees | 62 [2] |
AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. The company’s technology platforms create antibodies, small molecules, and vaccines to address a broad spectrum of neurodegenerative indications. It offers its therapies to address Alzheimer disease and neurodegenerative diseases, such as Parkinson’s, Down syndrome, and glaucoma.
AC Immune SA was founded in 2003 and is based in Lausanne, Switzerland. [3]
Contents
History
Controversies
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| February 23, 2019 | GSS_Hope4Cure | AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnost… https://t.co/owaYYLfmNL |
| February 23, 2019 | bulletin_en | AC Immune SA $ACIU Analysts See $0.12 EPS as of March, 19 https://t.co/4OC3grHWyT |
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines
- ↑ http://www.acimmune.com/en/senior-management-team/
- ↑ http://www.nasdaq.com/markets/ipos/company/ac-immune-sa-995734-81000
- ↑ http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=22309440
Top Authors
Verification history
812 days ago- View all verifications
